DMN:FRA
Diamyd Medical AB
€0.071
arrow_upward
+1.14%(+0.00080) 1D
Oct 1, 8:02:44 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.07
High
€0.07
Low
€0.07
Mkt. cap
156.03M
Avg. vol.
17.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
44
Open
€0.07
High
€0.07
Low
€0.07
Mkt. cap
156.03M
Avg. vol.
17.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
44
News stories
From web sources and news partners
Simply Wall Street
·
5 minutes ago
Learn Why The Bull Case For Fastly (FSLY) Could Change Following Comcast Edge Partnership
MarketBeat
·
4 minutes ago
Peloton Interactive, Inc. (NASDAQ:PTON) Receives Consensus Recommendation of "Hold" from Brokerages
TradingView
·
30 minutes ago
IXIC: Nasdaq Wraps Up Q3 with a Gain as Traders Enter Q4 with Mixed Feelings
Investor's Business Daily
·
3 hours ago
Dow Jones Futures: Micron Earnings Crush Views, S&P 500 At Critical Level As Treasury Yields Rise
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB